Efficient patient enrollment in clinical trials is essential to advancing medical research and improving cancer treatment outcomes. Despite the potential benefits, enrolling patients in these trials remains a significant challenge for oncologists. While 70% of cancer patients express interest in participating in trials, only 7.1% are successfully enrolled. This gap highlights substantial barriers that hinder recruitment efforts, limiting access to crucial research opportunities.
Some comprehensive Cancer Centers tackle this issue by developing in-house tools that monitor trial performance and predict enrollment rates. One premier cancer center, the University of Kansas Cancer Center (KUCC), is doing just that. As described in the paper Accrual Prediction Program: A web-based clinical trials tool for monitoring and predicting accrual for early-phase cancer studies, the Trial Accrual Prediction Program developed at KUCC was designed to address challenges in patient recruitment for clinical trials by providing real-time insights into patient enrollment progress, allowing for better planning and adaptation of recruitment strategies.
This program has been very effective for KUCC, and Inspirata is excited to partner with them to facilitate the applications dissemination through our powerful platform. Inspirata's Trial Navigator™ assists in matching eligible patients to suitable trials using AI and natural language processing (NLP), helping oncologists and researchers conduct high-accruing trials without bias. Inspirata plans to expand Trial Navigator’s functionality by incorporating the features of KUMC’s Accrual Prediction Program, creating the Trial Accrual Prediction Application.
This partnership aims to commercialize KUCC’s innovative tool, making it accessible to a broader range of research institutions and cancer centers. By providing a comprehensive solution to predict and monitor trial accrual, the tool will empower research institutions to overcome recruitment challenges, reduce delays, and expedite the development of new cancer treatments. Ultimately, this will enhance patient participation, accelerate research, and bring life-saving therapies to market more efficiently.
In essence, the collaboration between Inspirata and KUCC has the potential to transform the landscape of clinical trials, benefiting not only research institutions but, more importantly, cancer patients eager for new treatments.
Have any questions? Contact us